Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (3960)	1/20/1998 3:37:00 PM
From: biowa	Respond to of 9719

V1, << <Cytovia spin-off> the only benefit they talked about was reducing the burn rate.>> Thanks. BTW, you're slipping, Batman (3968). <<Biotechs are different. The assets lie in the skill and knowledge of the key employees and these folks who are in high demand and rarely stay in failing companies. The more I look at down and out biotechs the more I conclude that there is good reason for their failure.>> I would take it from a slightly different perspective: IMHO, the assets lie in the combination and synergy of people across the functions, rather than in "key" people. Give me an investment in a company with good people in science, marketing, clinical affairs, business development, etc. over one with excellence in one or two of those areas and incompetence in the rest. I do have to agree with Rick Harmon, though, there is a difference between a stinker and those that are simply down and out (IMO,usually its the veracity of management). biowa